Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotech company developing bacteriophage therapeutics, announced its participation in the upcoming H.C.

Rhea-AI Summary

Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotech company developing bacteriophage therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Deborah Birx, M.D. will deliver a corporate presentation on September 10, 2025, from 1:30-2:00 PM ET in New York. The company specializes in developing treatments for antibiotic-resistant and difficult-to-treat bacterial infections.

Argus Sep 4 session

-1.00% close to close Open Argus

Details

News Market Reaction – ARMP

On Sep 4, the day this news came out, ARMP closed 1.00% below the previous close.

Data tracked by StockTitan Argus for the Sep 4 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held in New York from September 8-10, 2025.

Armata's presentation is scheduled for Wednesday, September 10, from 1:30-2:00 PM ET.

To schedule a one-on-one meeting, please contact your H.C. Wainwright representative.

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices manufacturing to support full commercialization.

Media Contacts:

At Armata:
Pierre Kyme
ir@armatapharma.com
310-594-7035

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302540984.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Armata Pharmaceuticals (ARMP) presenting at the H.C. Wainwright Conference 2025?

Armata Pharmaceuticals will present on Wednesday, September 10, 2025, from 1:30-2:00 PM ET at the conference in New York.

Who will be presenting for Armata Pharmaceuticals at the H.C. Wainwright Conference?

Deborah Birx, M.D., Chief Executive Officer of Armata Pharmaceuticals, will deliver the corporate presentation.

What type of therapeutics is Armata Pharmaceuticals (ARMP) developing?

Armata is developing high-purity, pathogen-specific bacteriophage therapeutics for treating antibiotic-resistant and difficult-to-treat bacterial infections.

How can investors arrange meetings with Armata Pharmaceuticals at the conference?

Investors can schedule one-on-one meetings with Armata through their H.C. Wainwright representative.